ZA200600027B - Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof - Google Patents

Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof

Info

Publication number
ZA200600027B
ZA200600027B ZA200600027A ZA200600027A ZA200600027B ZA 200600027 B ZA200600027 B ZA 200600027B ZA 200600027 A ZA200600027 A ZA 200600027A ZA 200600027 A ZA200600027 A ZA 200600027A ZA 200600027 B ZA200600027 B ZA 200600027B
Authority
ZA
South Africa
Prior art keywords
chitosan
derivative
protein
pharmaceutical formulations
intranasal administration
Prior art date
Application number
ZA200600027A
Other languages
English (en)
Inventor
Dyer Ann Margaret
Cheng Yu-Hui
Watts Peter James
Smith Alan
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Publication of ZA200600027B publication Critical patent/ZA200600027B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200600027A 2003-07-04 2006-01-03 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof ZA200600027B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0315632.0A GB0315632D0 (en) 2003-07-04 2003-07-04 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ZA200600027B true ZA200600027B (en) 2009-08-26

Family

ID=27741549

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200600027A ZA200600027B (en) 2003-07-04 2006-01-03 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof

Country Status (14)

Country Link
US (2) US7662403B2 (fr)
EP (1) EP1641434B1 (fr)
AT (1) ATE417599T1 (fr)
AU (1) AU2004255515B2 (fr)
CA (1) CA2531239C (fr)
DE (1) DE602004018496D1 (fr)
DK (1) DK1641434T3 (fr)
ES (1) ES2319995T3 (fr)
GB (1) GB0315632D0 (fr)
NZ (1) NZ544718A (fr)
PL (1) PL1641434T3 (fr)
PT (1) PT1641434E (fr)
WO (1) WO2005004838A1 (fr)
ZA (1) ZA200600027B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
GB2438834A (en) * 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
AU2007272970C1 (en) * 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
EP2364153B1 (fr) 2008-11-12 2015-05-06 Synedgen, Inc. Dérivés de chitosan pour optimiser la croissance animale
EP2782590A4 (fr) * 2011-11-23 2016-08-03 Durect Corp Compositions de transport de medicaments biodégradables, stérilisées par un rayonnement
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
CN107530373B (zh) 2015-02-01 2023-12-29 欧森尼克斯有限责任公司 用于在患者中口服施用的含有砷的高表面积冻干组合物
WO2019245373A1 (fr) 2018-06-22 2019-12-26 Bioralix B.V. Formulations de polymères biologiques pour administration par voie orale

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
JPH07118170A (ja) * 1993-10-19 1995-05-09 Dot:Kk 経鼻吸収薬物用キャリヤ、生理活性ペプチド組成物およびその製造法
US20010053359A1 (en) * 1994-07-26 2001-12-20 Peter Watts Drug delivery composition for the nasal administration of antiviral agents
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
SE9403905D0 (sv) * 1994-11-14 1994-11-14 Astra Ab New formulations
GB9522351D0 (en) 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
EP0943326B2 (fr) 1996-02-27 2006-12-20 Teijin Limited Composition pulverulente destinee a une administration nasale
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
PT994726E (pt) 1996-07-10 2002-09-30 West Pharm Serv Drug Res Ltd Composicoes adequadas para entrega de genes a celulas epiteliais
GB9700624D0 (en) * 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
EP1637154A3 (fr) * 1998-07-08 2007-08-15 Kirin-Amgen Inc. Poudre contenant un principe actif d'un haut poids moléculaire à l'administration par les muqueuses
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
EA006384B1 (ru) 2000-07-31 2005-12-29 Нюкомед Данмарк А/С Композиция фентанила для интраназального введения
CA2466982A1 (fr) * 2001-11-19 2003-05-30 Becton, Dickinson And Company Compositions pharmaceutiques sous forme particulaire
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
ES2319995T3 (es) 2009-05-18
NZ544718A (en) 2009-06-26
AU2004255515B2 (en) 2009-04-30
DK1641434T3 (da) 2009-04-06
WO2005004838A1 (fr) 2005-01-20
EP1641434B1 (fr) 2008-12-17
DE602004018496D1 (de) 2009-01-29
AU2004255515A1 (en) 2005-01-20
WO2005004838A8 (fr) 2005-03-17
EP1641434A1 (fr) 2006-04-05
US20060120973A1 (en) 2006-06-08
CA2531239C (fr) 2011-05-24
US7662403B2 (en) 2010-02-16
CA2531239A1 (fr) 2005-01-20
AU2004255515A2 (en) 2005-01-20
GB0315632D0 (en) 2003-08-13
PT1641434E (pt) 2009-03-19
ATE417599T1 (de) 2009-01-15
PL1641434T3 (pl) 2009-08-31
US20100021553A1 (en) 2010-01-28
US8481070B2 (en) 2013-07-09

Similar Documents

Publication Publication Date Title
AP1646A (en) Flow resistance modulated aerosolized active agent delivery.
WO2002092147A3 (fr) Optimisation des proprietes moleculaires et formulation de proteines delivrees par inhalation
AU2003295614A1 (en) Delivery of pharmaceutical agents via the human insulin receptor
ZA200600027B (en) Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof
MXPA05010565A (es) Sistemas de suminsitro de farmacos que comprenden un ingrediente activo encapsulado.
AU1200501A (en) Drug delivery catheters that attach to tissue and methods for their use
BG104720A (en) Aerosolized active agent delivery
AP1760A (en) Platinum derivative pharmaceutical formulations.
AU2003239531A1 (en) Protein cages for the delivery of medical imaging and therapy
FR11C0017I2 (fr) Utilisation de spinosad ou d'une formulation comprennant spinosad
DK1499360T3 (da) Formulering omfattende buprenorphin
AU2003213675A1 (en) Controlled delivery patch of active ingredient
AU2003207016A1 (en) Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor for the treatment of inflammatory and allergic conditions
DK1392254T3 (da) Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
WO2003079993A3 (fr) Preparations d'hormone de croissance humaine (hch) destinees a etre administrees par voie pulmonaire
GB9918559D0 (en) Novel pharmaceutical formulation
IL145069A0 (en) Pharmaceutical compositions for delivery to an external wall of a body passageway or cavity
AU2003231260A1 (en) Catechin multimers as therapeutic drug delivery agents
AU2002332836A1 (en) Stabilizing catheter for protein drug delivery
WO2003007876A3 (fr) Conjugues acide amine-acide gras normal et utilisations therapeutiques
AU2273301A (en) Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer
AU2002253785A1 (en) Catheter and implants for the delivery of therapeutic agents to tissues
FR2864090B1 (fr) Derives carboxy-reduits de l'acide hyaluronique, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
WO2004073627A3 (fr) Methode et compositions therapeutiques pour administration topique
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them